Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study

• Principais autores: Germán Áñez (Autor), James Hedrick (Autor), Michael W. Simon (Autor), Shane Christensen (Autor), Robert Jeanfreau (Autor), Eddy Yau (Autor), Judy Pan (Autor), Emilia Jordanov (Autor), Mandeep S. Dhingra (Autor)
• Formato: Livro
• Publicado em: Taylor & Francis Group, 2020-06-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

The quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) was assessed as a booster in this Phase III trial (NCT02752906). Quadrivalent meningococcal conjugate vaccine (MCV4)-primed individuals aged ≥15 y (n = 810) were randomized 1:1 to receive a single booster dose of MenACYW-TT...